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Abstract 
In the last 10 years, the growing approval
and marketing of biological agents has signifi-
cantly ameliorated the outcomes of rheuma-
toid arthritis and spondyloarthritis patients
suffering from active and refractory disease
despite conventional treatments. As patent
protection of many biopharmaceuticals will
expire in the next years, biosimilars could be
proximally introduced. Such agents could be
marked only when they will be proven, through
in vitro and in vivo studies, to be similar
enough to the original comparator in term of
quality, efficacy and safety. As biosimilars are
less expensive than corresponding originators,
a wider use of these drugs may substantially
cut off the expenditure of biopharmaceuticals.
Nevertheless, ongoing debate exists in scien-
tific community: the intrinsic complex and
large structure of biologic molecules besides
the natural variability in the manufacturing
processes might lead to a slightly different
product respect to the original one, so that rel-
evant implications for efficacy and safety con-
cerns might arise, especially in the long-term
period. Immunogenicity and extended indica-
tions of biosimilars represent further matter of
discussion, too. Thus, before their approval
and marketing, specific guidelines and steps
imposed by national and/or international regu-
latory agencies should be followed along with
the respect of scientific societies position in
each specific contest. 
Introduction
The recent advent of biosimilars represents
the most innovative aspect in the treatment of
rheumatoid arthritis (RA) with biological dis-
ease modifying anti-rheumatic drugs
(bDMARDs). As recently introduced by Smolen
et al.,1 such innovation might require, as a
consequence, the proposal of introducing a
new nomenclature for all the available
DMARDs for RA patients: synthetic (or chemi-
cal) DMARDs, divided into conventional syn-
thetic (csDMARDs: like methotrexate, and all
the other methotrexate-equivalent DMARDs)
and targeted synthetic (tsDMARDs, such as
tofacitinib, fostamatinib, baricitinib or apremi-
last, or agents not focused primarily on rheu-
matic diseases, such as imatinib or ibrutinib
respectively), and biologic DMARDs, including
biological original and biosimilars
(boDMARDs and bsDMARDs, respectively).1
Such proposed nomenclature covers not
only the simple nosological issues, in order to
specify the clear nature and identity of each
compound, but it also indirectly arises several
problems like the complexity of approval
process by authorities, drug production and
marketing. This new recognized drug classifi-
cation also represents the starting point to
allow a better comparison among such differ-
ent classes of agents.
Study design
A revision of the most relevant issues relat-
ed to biosimilars in rheumatology has been
assessed. In the following sections several top-
ics will be briefly discussed in accordance with
the available knowledge in the field. 
Biosimilars: definition
Biosimilars are biological agents that essen-
tially copy the primary, secondary and tertiary
structures of a parent originator compound,
ideally even including its post-translational
modifications; in addition, they should convey
similar efficacy and safety as the original pro-
tein.2 The potential availability of biosimilar
versions of these targeted drugs might promise
larger accessibility to biopharmaceuticals with
similar efficacy and safety but at a lower cost,
possibly marketed whenever original branded
have expired. These second-generation prod-
ucts could not be merely considered as identi-
cal follow-on products, in comparison to the
first generation ones, as it happens for simpler
chemical drugs. In fact, while for chemical
compounds a generic drug is intended to con-
tain the same active component, normally a
small molecule, which is qualitatively and
quantitatively identical to the reference drug,
although the excipients may differ, for biologi-
cal compounds, like anti-TNF agents, biosimi-
lars might not be fully identical to the original
comparator. The greater dimensions together
with the more complexity and spontaneous
and/or induced variability of such biologic mol-
ecules, partly dependent on spontaneous/
forced minor and major manufacturing modifi-
cations, should explain the great challenge of
biosimilars. Specifically, many factors should
be taken into account in the field: i) a large
biologic, such as a monoclonal antibody, meas-
ures about 150 Kda and has more than a 1000
aminoacids; ii) it usually degrades over time,
requiring special storage to maintain stability;
iii) expression systems should be stable too;
iv) manufacturing changes are not rare, some-
times even directly done by the original devel-
opers of biologics in order to find additional
beneficial effects; v) in addition, some specific
post-translational modifications may also be
critical for function. As a consequence, while
marketing the generic form of simple chemical
compounds requires only the preventive
demonstration of its bioequivalence respect to
the reference drug, that is normally done in
healthy volunteers to compare the bioavailabil-
ity between the tested and the reference prod-
uct, marketing a biosimilar requires a more
complex and longer multi-step process which
not always achieves success (Table 1). Taking
this into account, we can wonder whether
biosimilars could really result similar enough
to the original products. This could explain the
existence of a great regulatory framework as a
fundamental pre-requisite to admit their final
approval and marketing: pre-clinical and clini-
cal studies are preliminary required with
important implications. In fact, biosimilars
should be intended to be sufficiently similar to
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the reference products, that there is no clini-
cally meaningful difference between them in
terms of purity, safety, and efficacy. The same
therapeutic effect could be thus obtained with
a cheaper version of the drug, which could be
marketed only after the patent of a branded
agent has definitively expired.
Biosimilars andpharmaco-economical issues
Although the world-life prevalence of RA and
ankylosing spondylitis (AS) is not high, the
chronic course of such diseases and their irre-
versible consequences in term of damage and
disability affecting relatively young and work-
ing patients, have great impact on social and
economical panorama. Direct and indirect
costs related to patients and disease them-
selves are high, and they have been progres-
sively implemented by drugs costs, especially
after the introduction of biological agents. One
can wonder whether such implemented drugs
cost might be counterbalanced by saving other
resources or by avoiding other health care
costs through better patients outcomes, espe-
cially with functional and work ability preser-
vation. Cost-effectiveness analyses should be
optimized in order to quantify the effect of
such new treatments, like bDMARDs, in chron-
ic diseases, but concerns exist due to the fact
that clinical trials are generally short com-
pared with the duration of the disease itself,
and limited pharmaco-economical data on the
use of this new treatments are available in
clinical practice.3,4 In this contest, a disease
model should be created as a baseline para-
digm to compare cost-effectiveness of new
treatments in RA: it must comprehend epi-
demiologic data related to the disease itself,
information about resource consumption at
any disease severity level, entity of direct and
indirect costs related to patients morbidity and
disability. The evidences so far available in
this direction seem to support and admit
advantages of TNF antagonists, compared with
traditional therapies for RA; biosimilars could
be of further additional value for such pharma-
co-economical purposes: similar efficacy and
safety profiles could go ahead with greater
cost-saving prospects and, as a consequence,
larger access for patients. 
Biosimilars and regulatoryconcerns
All the regulatory agencies, like the Food
and Drug Administration (FDA) and the
European Medicines Agency (EMA) necessari-
ly require a multi-step process through which
in vitro and in vivo experiments could allow
equivalence demonstration among original
and biosimilars, relying on precise and specific
preliminary definitions, which should be final-
ly satisfied. 
For the EMA, a biosimilar is a [...] biological
medicinal product that contains a version of
the active substance of an already authorized
original biological medicinal product (refer-
ence medicinal product). A biosimilar demon-
strates similarity to the reference medicinal
product in terms of quality characteristics, bio-
logical activity, safety and efficacy based on a
comprehensive comparability exercise. 
According to the FDA, a biosimilar could be
intended when [...] the biological product is
highly similar to the reference product notwith-
standing minor differences in clinically inactive
components. The FDA specifically requires that
clinical studies must show that there are no
clinically meaningful differences between the
biosimilar and the reference biopharmaceutical
in the safety, purity, and potency of the product,
while the EMA requires an appropriate compa-
rability exercise in order to demonstrate that the
similar biological and reference medicinal prod-
ucts have similar profiles in terms of quality,
safety and efficacy.5,6 These studies must
demonstrate that pharmacokinetics and phar-
macodynamics, efficacy, and safety of the
biosimilar are essentially equivalent to those of
the innovator biopharmaceutical at the same
dose, and that the biosimilar is not more
immunogenic than the reference product.
Because the therapeutic doses of the innovator
biopharmaceutical have already been estab-
lished and the biosimilar must be administered
at the same doses, the development program for
a biosimilar does not need to include dose-rang-
ing studies in patients, like for the original
product. Instead, at least one non-inferiority
clinical trial comparing the biosimilar and the
innovator reference biopharmaceutical is
required to show that there are no significant
differences in efficacy between the two drugs,
and indeed that a biosimilar is non-inferior to
the original compound in term of frequency and
timing of achievement of predefined responses.
CT-P13 is a biosimilar infliximab that was
compared to innovator infliximab both with in-
vitro analytical studies, which demonstrated
similar biologic effects (tumor necrosis factor
/TNF  neutralizing potency, and complement-
dependent cytotoxicity activity) and with in
vivo studies, which showed similar clinical
profiles. Thus, CT-P13 was studied in two ran-
domized, double-blind, parallel-group, prospec-
tive clinical trials to assess its potential non-
inferiority to the reference product with
respect to efficacy and safety outcomes over 30
weeks. The PLANETAS trial was a phase 1
study that compared the pharmacokinetics,
efficacy, and safety of CT-P13 to those of inno-
vator infliximab, each as monotherapy in
patients with AS.7 The PLANETAS trial
achieved its primary and secondary endpoints,
demonstrating that pharmacokinetic profiles
of CT-P13 and innovator infliximab were
equivalent between weeks 22 and 30, and high-
ly similar between treatment groups for each
of the six intravenous doses that were infused
over the 30-week study. The PLANETRA trial
was a phase 3 study that evaluated the efficacy
and safety of CT-P13 compared to innovator
infliximab, each in combination with
methotrexate, in patients with active RA.8 In
both studies, a quite similar clinical efficacy
                             Review
[page 24]                                                         [Rheumatology Reports 2014; 6:5518]
Table 1. Some of the available ongoing biosimilars and corresponding results of approving process. 
Product                                       Results
Interferon α2A                                      No approval
Interferon β1A: avonex                        Initial production stopped; subsequent product improved
rHuEPO: eprex                                       Aggregate formation led to development of anti-EPO antibodies and 175 cases of pure red cell aplasia happened in 1998-2004
p55TNF-R:Ig: lenercept                        Development discontinued
Darbopoetin α: aranesp                      Iterative manufacturing change
Rituximab: mabthera                            Iterative manufacturing change
p75TNF-R:Ig: etanercept: enbrel       Iterative manufacturing change 









was demonstrated in clinical end-points in
either RA and AS patients in term of ACR and
EULAR responses and ASAS criteria, respec-
tively. Time of response was similar in both
patients’ populations too, with early effect
maintained up to 30 and 54 weeks, as recently
presented at EULAR Congress in Madrid in
2013: rapidity and sustainability have been
finally demonstrated to be similar for both
compounds.7,8
Biosimilars and extensionof indications
After initial approval, FDA and EMA also
advocate the introduction of biosimilars for
additional and different indications, by extrap-
olation from the reference drug results and
from data of biosimilar in the primary indica-
tion, without requiring substantial clinical and
specific data: this process is called indication
extrapolation and it might allow the extension
of indication for the biosimilar itself.2 For
instance, in 2013 the EMA recommended the
marketing authorization of CT-P13, the world’s
first follow-on monoclonal antibody claimed to
be biosimilar to infliximab (Remicade®,
Janssen Biotech Inc., Horsham, PA, USA).9 The
approval or recommended approval of CT-P13
was based on a single equivalence trial con-
ducted in patients with RA, supplemented by a
pharmacokinetic study on AS.7,8 What was
unique about this approval was that four other
indications of infliximab (i.e., Crohn’s disease,
ulcerative colitis, psoriatic arthritis, and
plaque psoriasis) were granted to CT-P13,
although the product was not tested in these
indicated populations. Such issue raised sever-
al concerns due to the observations that not all
the extrapolation requirements by the regula-
tory agencies have been largely satisfied by the
existing scientific and clinical data. RA itself
might be not a sensitive model for all the other
indications; moreover, clinically relevant
mechanisms of action for infliximab, and
thereby for CT-P13, could differ across the
approved indications. If the biosimilar and the
innovator biopharmaceutical share the same
mechanisms of action in the various disease
states and the requirements for licensure as a
biosimilar have been met, the biosimilar might
be licensed for use in some or all of the other
indications for which the innovator biophar-
maceutical is licensed. Although, careful mon-
itoring is mandatory especially for such indica-
tions not directly explored.
Specific extrapolation criteria have been
developed by regulatory agencies in order to
mitigate concerns. Extended indications
should be properly indicated in the product
label: where the mood of action of investigated
drugs varies across different indications or
they are not fully understood, separated trials
should be performed before extrapolation;
individual patients and/or disease characteris-
tics could influence results in efficacy and
safety so that careful consideration must be
given to such elements of variability.2 It
remains to be seen whether physicians will be
comfortable with prescribing in clinical prac-
tice a medication for an extended indication
without supporting full phase III data.
Biosimilars and immunogenicity
The regulatory agencies absolutely require
that the immunogenicity profile of follow-on
products should be sufficiently characterized
before extrapolation to other indications is
sought. This might be taken into account,
considering that the proportion of patients
developing immunogenicity after treatment
with infliximab varied widely by indication: it
is higher in Crohn’s disease (up to 61%),
ranging between 20 and 51% in psoriasis,
lower in RA patients, probably partly due to
the licensed indication of co-administration
with methotrexate.10-12 This further explains
why extrapolation of the results on the
immunogenicity profile of CT-P13 could be
inappropriate. In PLANETRA and PLANETAS
trials, both CT-P13 and innovator infliximab
were immunogenic, and levels of anti-drug
antibodies were similar for both biopharma-
ceuticals. Specifically, antibodies to inflix-
imab were detected up to a third of AS
patients for each group (at week 24 in 27.4%
and 22.5% for CT-P13 or innovator infliximab
as monotherapy, respectively), and in nearly
half of RA patients treated with either CT-P13
or innovator infliximab, each in combination
with methotrexate. In both of these clinical
trials, the proportion of clinical responders
was lower among those with anti-drug anti-
bodies than among those without. In addition,
it has been recently reported that a rituximab
biosimilar has produced anaphylactic reac-
tions after the patients were switched to the
biosimilar in Mexico and this raises the real
issue of what should be the real definition of
the biosimilarity and of the bioequivalence in
terms of safety and immunogenicity.13 For the
EMA agency, specific end-points should be
addressed for the full characterization of the
immunogenicity profile of biosimilars: char-
acteristics of the drug itself and its short and
long-term exposure effects, but also of the
underlying disease, should be entirely consid-
ered. Therefore, immunogenicity of non
endogenous proteins arises several concerns
for safety and efficacy issues: as a direct
corollary to this, biosimilars should have their
own specific name and traceability both for
epidemiological purposes, like in registries,
and for spontaneous reporting/healthcare
databases, too.
Biosimilars: the present
All biosimilars, intended globally as a group,
now labeled by regulatory agencies enter into 3
categories: i) growth hormones, ii) erythropoi-
etin, iii) granulocyte colony stimulating fac-
tors.14 In the field of rheumatology, currently,
several products labeled as biosimilars are
approved for treatment of RA in a number of
countries that, at the time of approval, did not
have stringent regulatory processes in place to
ensure comparability as defined by EMA and
FDA and had stringent economic pressure. For
these reasons, they could not be entirely consid-
ered as real biosimilars, but like intended
copies.2 On the contrary, currently, there are no
biosimilars definitively approved by EMA or FDA
for treatment of rheumatic diseases in Europe
and in the USA: several randomized controlled
trials (RCTs) are complete or on going in the
view to attain a biosimilar status for treatment
of rheumatic diseases.2 Earlier in 2012, the
South Korean company Celltrion, failed for EMA
approval of a biosimilar infliximab product, CT-
P13, based on results from the 2 previously pre-
sented large RCTs (PLANETRA and PLANETAS
studies). In the recent 2013 update of recom-
mendations for RA management, biosimilar
issue has been briefly addressed too, but the role
of such agents has not yet been fully specified.15
Biosimilars: the future
In the USA, the patent for innovator inflix-
imab does not expire until September 2018,
and thus biosimilar infliximab will not
become available in the USA until after that
date.16 Because the patent for innovator
infliximab in the European Union does not
expire until August 2014, CT-P13 will not be
marketed in European Union countries until
after that date. One financial analyst has esti-
mated that, by 2018, biosimilars will occupy a
40% share of the European market for thera-
peutic monoclonal antibodies.17 Specifically
in the italian panorama, the actually shared
position has been expressed in a defined
paper: most biosimilars, whenever definitely
approved, should be considered only for the
indications already tested through compara-
bility tests. Further extended indications, like
sero-negative arthritis related to inflammato-
ry bowel disease, off-label indications and/or
in pediatric populations, should be rigorously
explored with specific trials, attesting the
equivalence in efficacy and safety standards
towards the original comparator drug. 
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Considering all the issues discussed above,
we can conclude with a concise list of relevant
considerations on biosimilars: i) the complex
structure and the great dimension of biologi-
cal agents make difficult to produce really
identical follow-on products, since even
minor preventable and not-preventable modi-
fications during the manufacturing process
might considerably alter the drug structure
and its profile; ii) biosimilars are not generic
biologics and marketing approval for a
biosimilar requires specific in vitro and in
vivo studies which might support similarity
among compounds; similarity should not be
considered as a strict equivalence with the
original comparator, but as an effort for this,
without affecting the performance of the drug
itself; iii) each approved biosimilar is consid-
ered to be a new product with all of the asso-
ciated regulatory requirements; iv) compara-
tive clinical trials are critically important to
demonstrate the similarity in efficacy and
safety profiles between the biosimilar and the
innovator drug; this means that they have to
be tested in humans, and that the testing has
to be robust enough to detect any differences;
v) whenever fully available for use in clinical
practice, decisions to substitute one similar
product with another should only be made at
a physician’s discretion and each biologic
product must have a unique product name, so
as to precisely identify and trace it; vi) as a
consequence, interchangeability and
exchange could not be applied to biosimilars,
as it happens for simple chemical compounds:
a product is considered as interchangeable,
when it could substitute the originator with-
out the authorization of the health care
provider; on the contrary, up to now substitu-
tion of an originator with a biosimilar should
be defined at a state level and following the
opinion of a qualified health professional; vii)
specific clinical trials should be conducted for
other indications for which efficacy of the
original compounds has been already admit-
ted; viii) RA model can not be sufficient
enough to directly extend indication from it to
other different conditions; ix) in the pediatric
field, further studies are absolutely mandato-
ry before affirming equivalence; x) cost must
not override safety and efficacy; the cost of
biosimilars is clearly less than that of the
brand name biologic to which it is similar, but
this could not be the most relevant aspect to
consider in the choice of the drug; xi) strict
post-marketing surveillance must be followed:
monitoring of biosimilars must conform to
the same rigorous standards as those used for
brand name biologics, with both real life reg-
istries and spontaneous reporting/healthcare
databases; xii) their traceability must be
assured through unique names. A registry,
similar to, or integrated with those currently
in use for original biological will be required
to provide longer term monitoring of each
specific, named, drug. Whether the required
funding will be provided by the industry or
other sources may vary.
Conclusions
In conclusion, in the immediate future the
clinician’s choice between the original and
biosimilar compounds should be completely
shared and discuss with the patients, in order
to clearly offer them the most efficacious and
safe treatments, and, if possible, at the cheap-
est cost; anyway, the main driver in this choice
should always be the existence of sufficient
evidence-based-medicine data along with a
patient-first approach, that is in the first and
main interest and benefit to the patients them-
selves.18 Thus, biosimilars might offer a good
alternative to the existing biologic drugs only
when complete and robust data might ensure
their extensive use without safety and efficacy
concerns for both tested and non tested
(extended) indications.
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